Dose-matched placebo

DRUG2 trials

Sponsors

Forest Laboratories, Merck Sharp & Dohme LLC

Conditions

Major Depressive DisorderRheumatoid Arthritis (RA)

Phase 2

Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

TerminatedNCT01569152

Merck Sharp & Dohme LLCRheumatoid Arthritis (RA)

Start: 2012-05-22End: 2013-10-03Updated: 2019-03-27

Phase 4

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

CompletedNCT01473394

Forest LaboratoriesMajor Depressive Disorder

Start: 2011-12-31End: 2013-02-28Updated: 2014-04-03

Related Papers

Vilazodone efficacy in subgroups of patients with major depressive disorder

International Clinical Psychopharmacology2018-03-3011 citations

Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials.

2016-12-02

Vilazodone in patients with generalized anxiety disorder

International Clinical Psychopharmacology2015-08-2025 citations

A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.

2015-04-1729 citations

Efficacy and Safety of Vilazodone in Major Depressive Disorder

The Journal of Clinical Psychiatry2014-11-2461 citations

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder

International Clinical Psychopharmacology2014-11-149 citations